Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 2Terminated 2Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Thoracic 1Genitourinary 1

Conditions

Colorectal Neoplasms 255Rectal Neoplasms 155Colonic Neoplasms 128Stomach Neoplasms 100Pancreatic Neoplasms 94Breast Neoplasms 77Esophageal Neoplasms 76Neoplasm Metastasis 58Squamous Cell Carcinoma of Head and Neck 56Head and Neck Neoplasms 56Neoplasms 43Adenocarcinoma Of Esophagus 37Esophageal Squamous Cell Carcinoma 27Adenocarcinoma 25Unspecified Adult Solid Tumor, Protocol Specific 15Carcinoma, Hepatocellular 15Parkinson Disease 4, Autosomal Dominant Lewy Body 13Anus Neoplasms 12Keratosis, Actinic 11Gastrointestinal Neoplasms 11Biliary Tract Neoplasms 11Gallbladder Neoplasms 10Carcinoma, Squamous Cell 10Urinary Bladder Neoplasms 9Nasopharyngeal Carcinoma 9Liver Neoplasms 9Cholangiocarcinoma 9Carcinoma 9Bile Duct Neoplasms 9Recurrence 8

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Fluorouracil × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡